Free Trial

Exact Sciences (EXAS) Stock Price, News & Analysis

$49.84
-4.24 (-7.84%)
(As of 05/24/2024 04:00 PM ET)
Today's Range
$49.65
$54.00
50-Day Range
$49.84
$74.26
52-Week Range
$49.65
$100.77
Volume
6.01 million shs
Average Volume
2.56 million shs
Market Capitalization
$9.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.40

Exact Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
91.4% Upside
$95.40 Price Target
Short Interest
Healthy
4.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.51mentions of Exact Sciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$2.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.15) to ($0.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.50 out of 5 stars

Medical Sector

91st out of 921 stocks

Medical Laboratories Industry

4th out of 19 stocks

EXAS stock logo

About Exact Sciences Stock (NASDAQ:EXAS)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Stock Price History

EXAS Stock News Headlines

Exact Sciences (NASDAQ:EXAS) Trading Down 5.6%
Cologuard’s Market Share Surge Powers Buy Rating
Piper Sandler Keeps Their Buy Rating on Exact Sciences (EXAS)
Q1 2024 Exact Sciences Corp Earnings Call
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
5/27/2024
Next Earnings (Estimated)
8/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,600
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$95.40
High Stock Price Target
$121.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+91.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$-204,150,000.00
Pretax Margin
-9.38%

Debt

Sales & Book Value

Annual Sales
$2.50 billion
Cash Flow
$0.02 per share
Book Value
$16.98 per share

Miscellaneous

Free Float
182,131,000
Market Cap
$9.20 billion
Optionable
Optionable
Beta
1.26

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

EXAS Stock Analysis - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price target for 2024?

13 brokerages have issued 1 year price objectives for Exact Sciences' shares. Their EXAS share price targets range from $80.00 to $121.00. On average, they anticipate the company's stock price to reach $95.40 in the next year. This suggests a possible upside of 91.4% from the stock's current price.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2024?

Exact Sciences' stock was trading at $73.98 at the beginning of 2024. Since then, EXAS stock has decreased by 32.6% and is now trading at $49.84.
View the best growth stocks for 2024 here
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our EXAS earnings forecast
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Wednesday, February, 21st. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.26. The medical research company earned $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative net margin of 9.48% and a negative trailing twelve-month return on equity of 7.12%. The business's revenue for the quarter was up 17.0% on a year-over-year basis. During the same period last year, the firm posted ($0.72) EPS.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.65%), Capital World Investors (7.06%), Champlain Investment Partners LLC (1.22%), Sumitomo Mitsui Trust Holdings Inc. (1.09%), Baillie Gifford & Co. (0.93%) and Nikko Asset Management Americas Inc. (0.83%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Daniel J Levangie, Everett Cunningham, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy and Sarah Condella.
View institutional ownership trends
.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Exact Sciences have any subsidiaries?
The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More
This page (NASDAQ:EXAS) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners